Ani Pharmaceuticals (ANIP) Income towards Parent Company (2011 - 2026)

Ani Pharmaceuticals has reported Income towards Parent Company for 16 years, with the latest figure at $29.5 million in Q1 2026.

• Quarterly Income towards Parent Company rose 88.0% year-over-year to $29.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.2 million (up 537.39% YoY) and the FY2025 annual result came in at $78.3 million, up 522.94% from the prior year.
• Income towards Parent Company climbed to $29.5 million in Q1 2026 per ANIP's latest filing, from $27.5 million in the prior quarter.
• Over five years, Income towards Parent Company peaked at $29.5 million in Q1 2026 and troughed at -$24.2 million in Q3 2024.
• A 5-year average of $3.5 million and a median of $1.5 million in 2023 frame the typical range for Income towards Parent Company.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company sank 23472.09% in 2022, then surged 1144.71% in 2024.
• Over 5 years, Income towards Parent Company stood at -$4.3 million in 2022, then jumped by 126.96% to $1.2 million in 2023, then sank by 990.12% to -$10.3 million in 2024, then surged by 367.96% to $27.5 million in 2025, then climbed by 7.15% to $29.5 million in 2026.
• According to Business Quant data, Income towards Parent Company over the past three periods registered $29.5 million, $27.5 million, and $26.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.